최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기약학회지 = Yakhak hoeji, v.58 no.3, 2014년, pp.171 - 180
이나영 (동덕여자대학교 약학대학) , 전인구 (동덕여자대학교 약학대학)
To enhance the in vitro permeation of lovastatin through excised hairless mouse and human cadaver skins, solubility was determined in various hydrophilic and lipophilic vehicles, and the effects of vehicles and penetration enhancers on the skin permeation from solution formulations were investigated...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
로바스타틴이란 무엇인가? | 로바스타틴은 천연에서 Aspergillus terreus 계통의 곰팡이류로부터 주로 생산되는 스타틴계 약물로서 1987년 미국식품의약국으로부터 Mevacor®라는 상품명으로 최초 승인을 받은 약물이다.1,2) 이 약물은 체내에서 에스테라제에 의해 그 락톤 환이 개열되어 활성형의 개환된 산으로 전환되는 프로드럭이다. | |
로바스타틴을 경구투여했을 때에 난용성, 난흡수성을 개선하기 위해 시도된 제제학적 방법에는 무엇이 있는가? | 3) 이와 같이 로바스타틴의 난용성, 난흡수성 및 부작용 등의 개선과 관련하여 경구 적용을 위한 여러 가지 제제학적 방법들이 시도되었다. 2-히드록시프로필-β-시클로덱스트린과의 포접 복합체 형성 및 혼연법에 의한 고체복합체,12) 고체지질 나노입자,13) 삼투압 펌프 정제,14) 변형 메뚜기콩 검과의 고체분산체,15) 생분해 다공성 전분의 포말,16) 나노구조의 지질 담체17) 및 담즙산류를 이용한 십이지장 점막 투과 증진18) 등이 보고되었다. | |
경피 흡수 제제의 장점은 무엇인가? | 또한 피부 적용을 위한 제제설계로는 히드록시프로필메틸셀룰로오스, 유드라짓 RL 100 및 트리에틸시트레이트를 사용한 매트릭스 형 필름,19) 유드라짓 RL 100 및 RS 100의 혼합 필름,20) 탄성 리포솜21) 및 미셀 처방의 이온토포레시스22) 등이 보고되었다. 경피 흡수 제제는 약물의 초회통과효과 회피 및 안정적으로 낮은 혈중 농도 유지를 통한 이상약물반응을 줄일 수 있는 등의 장점이 있다. 하지만 이러한 경피 전달 시스템이 효과를 발휘하기 위해서는 약물이 피부 장벽을 투과하여 원하는 부위에 원하는 농도로 도달해야 한다. |
Alverts, A. W. : Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol., 62, J10 (1998).
Manzoni, M. and Rollini, M. : Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol. 58, 555 (2002).
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R. and Bernini, F. : New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413 (1999).
Shitara, Y. and Sugiyama, Y. : Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71 (2006).
Chuengsamarn, S., Rattanamongkoulgul, S., Suwanwalaikorn, S., Wattanasirichaigoon, S. and Kaufman, L. : Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46, 1011 (2010).
Xia, Z., Tan, M. M., Wei-Lynn Wong, W., Dimitroulakos, J., Minden, M. D. and Penn, L. Z. : Blocking protein prenylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15, 1398 (2001).
Jacobs, R. J., Voorneveld, P. W., Kodach, L. L. and Hardwick, J. C. H. : Cholesterol metabolism and colorectal cancers. Current Opinion Pharmacol. 12, 690 (2012).
Gauthaman, K., Fong, C. Y. and Bongso, A. : Statins, stem cells, and cancer, J. Cell. Biochem. 106, 975 (2009).
Silva, M. A., Swanson, A. C., Gandhi, P. J. and Tataronis, G. R. : Statin-related adverse events: A meta-analysis. Clin. Ther. 28, 26 (2006).
Wortmann, R. L., Tipping, R. W., Levine, J. G. and Melin, J. M. : Frequency of myopathy in patients receiving lovastatin. Am. J. Cardiol. 95, 983 (2005).
Bellosta, S., Paoletti, R. and Corsini, A. : Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109, III50 (2004).
Patel, R. P. and Patel, M. M. : Solid-state characterization and dissolution properties of lovastatin hydroxypropyl- ${\beta}$ -cyclodextrin inclusion complex. Pharm. Technol. 31, 72 (2007).
Suresh, G., Manjunath, K., Venkateswarlu, V. and Satyanarayana, V. : Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm. Sci. Technol. 8, E1 (2007).
Mehramizi, A., Asgari Monfared, E., Pourfarzib, M., Bayati, Kh., Dorkoosh, F. A. and Rafiee-Tehrani, M. : Influence of ${\beta}$ -cyclodextrin complexation on lovastatin release from osmotic pump tablets (OPT). DARU 15, 71 (2007).
Patel, M., Tekade, A., Gattani, S. and Surana, S. : Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques, AAPS Pharm. Sci. Technol. 9, 1262 (2008).
Wu, C., Wang, Z., Zhi, Z., Jiang, T., Zhang, J. and Wang, S. : Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs. Int. J. Pharm. 403, 162 (2011).
Chen, C. C., Tsai, T. H., Huang, Z. R. and Fang, J. Y. : Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm. 74, 474 (2010).
Shinde, A. J., Paithane, M. B. and More, H. N. : Development and in vitro evaluation of transdermal patches of lovastatin as a antilipidemic drug. Int. Res. J. Pharm. 1, 113 (2010).
Zawar, L. R., Bhandari, G. S. and Bari, S. B. : Formulation and evaluation of transdermal film of lovastatin. Res. J. Pharm. Biol. Chem. Sci. 2, 575 (2011).
Sharma, S., Sharma, A., Arora, S. and Gupta, A. : Preparation, characterization, in vitro & in vivo evaluation of elastic liposomal formulation of lovastatin. J. Pharm. Res. 4, 4074 (2011).
Sarvaiya, J. I., Kapse, G. K. and Tank, C. J. : Iontophoresis of micellar composition of lovastatin: study of affecting factors and in vitro permeation. J. Pharm. Res. 7, 327 (2013).
Kumar, R. and Philip, A. : Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Trop. J. Pharm. Res. 6, 633 (2007).
Gwak, H. S. and Chun, I. K. : Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int. J. Pharm. 236, 57 (2002).
Lee, J. H. and Chun, I. K. : Effects of various vehicles and fatty acids on the skin permeation of lornoxicam. J. Pharm. Invest. 42, 235 (2012).
Alvarez-Lueje, A., Pastine, J., Squella, J. A. and Nunez-Vergara, L. J. : Assessment of the hydrolytic degradation of lovastatin by HPLC. J. Chil. Chem. Soc. 50, 639 (2005).
Yang, D. J. and Hwang, L. S. : Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea. J. Chromatogr. A 1119, 277 (2006).
Huang, Z., Xu, Y., Li, Y. and Wang, Y. : Conversion investigation for lovastatin and its derivatives by HPLC. J. Chromatogr. Sci. 48, 631 (2010).
Lovastatin Tablets, The United States Pharmacopeia, Volume II, The United Book Press, Baltimore, pp. 2815-2817 (2009).
Barry, B. W. : Dermatological Formulations: Percutaneous Absorption, Marcel Dekker, New York, pp. 49-94 (1983).
Serajuddin, A. T., Ranadive, S. A. and Mahoney, E. M. : Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80, 830 (1991).
Williams, A. C. and Barry, B. W. : Penetration enhancers. Adv. Drug Del. Rev. 56, 603 (2004).
Ganem-Quintanar, A., Lafforgue, C., Falson-Rieg, F. and Buri, P. : Evaluation of the transepidermal permeation of diethylene glycol monoethyl ether and skin water loss. Int. J. Pharm. 147, 165 (1997).
Mura, P., Faucci, M. T., Bramanti, G. and Corti, P. : Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur. J. Pharm. Sci. 9, 365 (2000).
Hoelgaard, A., Mollgaard, B. and Baker, E. : Vehicle effect on topical drug delivery. IV. effect of N-methylpyrrolidone and polar lipids on percutaneous drug transport, Int. J. Pharm. 43, 233 (1988).
Golden, G. M., McKie, J. E. and Potts, R. O. : Role of stratum corneum lipid fluidity in transdermal drug flux. J. Pharm. Sci. 76, 25 (1987).
Komata, Y., Kaneko, A. and Fujie, T. : In vitro percutaneous absorption of thiamine disulfide through rat skin from a mixture of propylene glycol and fatty acid or its analog. Chem. Pharm. Bull. 40, 2173 (1992).
Santoyo, S. and Ygartua P. : Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application. Eur. J. Pharm. Biopharm. 50, 245 (2000).
Andega, S., Kanikkannan, N. and Singh, M. : Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin. J. Controled Release 77, 17 (2001).
Oertel, R. P. : Protein conformational changes induced in human stratum corneum by organic sulfoxides: an infrared spectroscopic investigation. Biopolymers 16, 2329 (1977).
Roy, S. D., Hou, S.-Y. E., Witham, S. L. and Flynn, G. L. : Transdermal delivery of narcotic analgesics: comparative metabolism and permeability of human cadaver skin and hairless mouse skin. J. Pharm. Sci. 83, 1723 (1994).
Ghosh, B., Reddy, L. H., Kulkarni, R. V. and Khanam, J. : Comparison of skin permeability of drugs in mice and human cadaver skin. Indian J. Exp. Biol. 38, 42 (2000).
Godin, B. and Touitou, E. : Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv. Drug Del. Rev. 59, 1152 (2007).
※ AI-Helper는 부적절한 답변을 할 수 있습니다.